Meta Avocado Delay Raises Competitive Concerns

Meta Avocado delay renews scrutiny of the company's AI roadmap and raises execution risk as META stock slipped about 3.2%, pressuring timelines.

March 13, 2026·2 min read
View all news articles
Flat vector of a server chip with dimming lights symbolizing the Meta Avocado delay and strained AI roadmap.

KEY TAKEAWAYS

  • Launch shifted from March to at least May, with June possible.
  • Internal testing found Avocado trails Gemini 3.0 and other leading models on reasoning and programming.
  • Delay raises execution risk for Meta's $115-$135 billion AI capital plan and near-term product timelines.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

The Meta Avocado delay was reported on March 12, 2026, renewing scrutiny of the company’s product timetable and raising investor concern about its near-term AI deliverables.

Avocado Delay Reveals Performance Shortfalls

Meta Platforms Inc. had targeted a March 2026 launch for Avocado, its next-generation AI model, but internal reports have pushed the public release to at least May 2026, with June also possible. The program was first disclosed publicly in December 2025.

Internal testing shows Avocado’s performance falls between Google’s Gemini 2.5 and Gemini 3.0 models. It trails Gemini 3.0 and leading AI systems from OpenAI and Anthropic in reasoning, programming, and writing tasks, though it outperforms Meta’s earlier models.

Strategic Impact and Market Reaction

Meta leadership has discussed temporarily licensing Google’s Gemini to power some products as a short-term solution, though no agreement has been announced.

Avocado is positioned as the successor to Meta’s Llama series and was described as a significant step in the company’s AI roadmap, which includes additional model releases and updates planned through 2026. The delay complicates this timeline and challenges the July 2025 expectation by CEO Mark Zuckerberg that new models would push the frontier within a year.

Earlier in 2026, Meta announced a capital expenditure plan of $115 billion to $135 billion for AI infrastructure and proprietary chip development. About nine months before the delay was reported, Meta hired Alexandr Wang and assembled an AI “super team,” with $14.3 billion attributed to that effort.

META stock declined 3.2% on March 13, 2026, as investors weighed the setback alongside the company’s heavy near-term AI commitments.

The postponement highlights execution risks in Meta’s costly AI buildout and raises questions about how quickly the company can close gaps with rivals while maintaining product timelines. Management’s public commitment to continued model releases this year keeps market focus on whether upgrades will restore competitive parity.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Cardinal Health Earnings Lift Guidance on Specialty Drugs

Cardinal Health Earnings Lift Guidance on Specialty Drugs

Cardinal Health earnings raised full-year EPS guidance to $12.40 to $12.60 on specialty drug strength, likely prompting repositioning into specialty names.

Super Micro Earnings Preview: Margins and Backlog

Super Micro Earnings Preview: Margins and Backlog

Super Micro earnings preview noted 15%-17% gross margin and a record backlog, putting traders on watch for backlog conversion into revenue and AI demand.

Trump Media Earnings: Q2 Loss Deepens

Trump Media Earnings: Q2 Loss Deepens

Trump Media earnings said non-cash digital-asset writedowns pushed $238.1 million Q2 loss, magnifying asset-price volatility and prompting traders to trim stakes.

Nvidia $500 Billion AI Financing Deal

Nvidia $500 Billion AI Financing Deal

Nvidia $500 billion AI financing pact with six Wall Street firms aims to mobilize capital for compute and data centers and could reprice chip demand.

Hims & Hers Q2 2026 Results: Guidance Raised

Hims & Hers Q2 2026 Results: Guidance Raised

Hims & Hers Q2 2026 Results lifted full-year revenue and adjusted-EBITDA guidance after subscriber gains, sharpening trader focus on growth versus margins.

AbCellera ABCL635 Phase 2 Results Lift Shares

AbCellera ABCL635 Phase 2 Results Lift Shares

AbCellera ABCL635 Phase 2 Results showed the drug met primary endpoints cutting hot flash frequency and severity and prompting a 24% stock rise.